Silver Nanoparticles as a Breakthrough Therapy for Irritable Bowel Syndrome

Mihaela Stoyanova; Vera Gledacheva; Miglena Milusheva; Iliyana Stefanova; Mina Todorova; Mina Pencheva; Kirila Stojnova; Stoyanka Nikolova

Previous Article in event

Computational Drug Likeness Studies of Selected Thiosemicarbazones: A Sustainable Approach to Drug Design

Next Article in event

Fabrication and characterization of GA-, EA-, and Rb-added perovskite solar cells passivated with DPPS

Silver Nanoparticles as a Breakthrough Therapy for Irritable Bowel Syndrome

¹,

²,

^{*

1, 3},

²,

¹,

²,

⁴,

¹ Department of Organic Chemistry, Faculty of Chemistry, University of Plovdiv, 4000 Plovdiv, Bulgaria
² Department of Medical Physics and Biophysics, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria
³ Department of Bioorganic Chemistry, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria
⁴ Department of General and Inorganic Chemistry with Methodology of Chemistry Education, Faculty of Chemistry, University of Plovdiv, 4000 Plovdiv, Bulgaria

Academic Editor: Alberto Jiménez Suárez

Published: 04 December 2024 by MDPI in The 5th International Electronic Conference on Applied Sciences session Nanosciences, Chemistry and Materials Science

Abstract:

The urgent need to address new health issues and enhance the effectiveness of treatment for a wide range of illnesses motivates the search for novel therapeutic agents as a current task in medicinal chemistry. Irritable bowel syndrome (IBS) is a multifactorial disorder characterized by altered intestinal motility, visceral hypersensitivity, dysfunction of the gut-brain axis. The nanoparticle system is one of the best ways to provide medication in a controlled manner. This study aims to develop drug-loaded silver nanoparticles (AgNPs) with mebeverine to improve the treatment of IBS.

A green, glucose-assisted method for the rapid synthesis and stabilization of AgNPs as a drug-delivery system is presented. The synthesized AgNPs were characterized by their UV-Vis spectra, TEM, zeta potential, and drug release. To assess their pharmacological potential, a series of ex vivo and in vitro experiments were conducted.

The mebeverine-based AgNPs were designed to relax smooth muscle tissue, providing a novel treatment option for IBS patients. Biological experiments showed that drug-loaded AgNPs have better spasmolytic activity compared to mebeverine.

In in vitro and ex vivo experimental models of inflammation, the nanoparticles significantly inhibited the production of pro-inflammatory cytokines and other mediators of inflammation. This activity suggests that synthesized AgNPs could be effective in treating chronic inflammatory conditions such as IBS, rheumatoid arthritis, and other autoimmune disorders.

Based on the results, synthesized AgNPs might be a promising medication delivery system and a useful treatment option for IBS. Our research into the synthesis and biological evaluation of drug-loaded AgNPs reveals their potential as novel therapeutic agents, capable of modulating multiple inflammation pathways. The promising results achieved so far underscore the importance of continued exploration and development in this area.

Acknowledgements: This study is part of Scientific Project KP-06-H73/11 of the National Fund for Scientific Research in Bulgaria, National Program for Basic Research Projects 2023.

Keywords: silver nanoparticles; irritable bowel syndrome; mebeverine; spasmolytic activity; anti-inflammatory activity

View Poster